Introduction
Prior to the development of viral inactivation procedures in the mid-1980s virtually all haemophilic patients who had previously received large pool plasma-derived factor concentrates were infected with hepatitis C virus (HCV). A considerable proportion of these patients were also infected with human immunodeficiency virus (HIV). Before the introduction of highly active antiretroviral treatment (HAART) in the mid-1990s HIV was considered to be the main viral infection in coinfected patients and the importance of HCV infection was underplayed. However, as HIV infection has been so effectively controlled by HAART there has been a heightened awareness of the potentially life-threatening effects of chronic HCV infection in coinfected patients. Consequently management of HCV infection in this cohort is now actively encouraged. This paper will discuss the interactions between HIV and HCV and cover aspects concerning the management of these viruses in coinfected haemophilic patients.
Interaction between HIV and HCV

Effect of HIV on HCV
It is well recognized that HIV accelerates the progression of chronic liver disease to liver failure and death in HCV-coinfected patients. HCV liver disease has become a major cause of death in HIVinfected patients stabilized on HAART [1] [2] [3] . In one large Spanish study of blood transfusion recipients and intravenous drug users 14.9% of coinfected patients had developed cirrhosis within the first 10 years of acquiring HCV infection compared with only 2.6% of HCV-monoinfected individuals [4] .
Makris et al. reported a higher rate of progression of HCV liver disease to cirrhosis in HIV-coinfected individuals in a cohort of UK haemophilic patients [5] . This observation was confirmed in a study by Benhamou et al. of a larger cohort of coinfected patients [6] . In a study of haemophilic patients Eyster et al. reported that progression to HCV-associated liver failure was accelerated by HIV [7] . Telfer et al. reported that after a median time from initial exposure to factor concentrate of 15 years coinfected haemophilic patients were 21-fold more likely to develop hepatic decompensation compared with HCV-monoinfected individuals [8] . In 1997 Darby et al. published a retrospective study of the UK haemophilia cohort in which as of 1 January 1993 the cumulative deaths from liver disease since first HCV exposure in HIV-infected patients was fourfold that of HIV-negative individuals (6.5% vs. 1.4%, respectively) [9] . In a more recent study of 134 haemophilic patients Lesens et al. reported a sevenfold overall increased liver disease-related death rate in coinfected individuals compared with the HCVmonoinfected group with an even higher rate in patients who had progressed to AIDS [10] . Hepatocellular carcinoma is a well-recognized complication of chronic HCV infection and appears to develop after a shorter duration of infection in HIV-infected patients [11] .
The exact way in which HIV accelerates chronic HCV liver disease has not been elucidated. As HIV itself does not appear to cause a hepatitis directly the effect is presumably mediated via suppression of the immune response against HCV. However, although there is evidence for this effect in that HCV viraemia tends to be higher in HIV-positive patients compared with those with HCV monoinfection both in haemophilic and non-haemophilic cohorts [12] [13] [14] , there is no conclusive evidence that the level of HCV viraemia is directly related to the severity of HCV liver disease [15, 16] .
There is evidence to suggest that more advanced HIV infection is associated with more rapid progression of HCV liver disease [17, 18] . However, the level of HIV viraemia is not correlated with severity of HCV liver disease [14] . In a study of 26 coinfected Greek haemophilic patients Delladetsima et al. reported no relationship between the stage of HIV infection and liver biopsy evidence of cirrhosis [19] . These authors observed restriction of necroinflammatory hepatitic activity to patients with early HIV infection and concluded that the development of cirrhosis with eventual progression to liver failure is initiated at this stage of HIV disease when immune function is still relatively well preserved.
As in HIV-negative individuals there is evidence to suggest that HCV genotype 1 may be associated with more rapid progression to cirrhosis than other genotypes in coinfected patients [19] [20] [21] .
Effect of HCV on HIV
Whether or not HCV infection accelerates the progression of HIV infection to AIDS and death remains unclear. One European and two North American studies conducted during the early 1990s concluded that HCV coinfection did not adversely influence survival in HIV-infected individuals [22] [23] [24] . Similarly four further studies, one before and three after the advent of HAART, concluded that HCV infection did not accelerate immunological and clinical progression of HIV disease [25] [26] [27] [28] . However, Piroth et al., in a French study of 119 HIV-and HCV-coinfected patients and 119 HIV-monoinfected individuals, observed that clinical progression of HIV was more rapid in the coinfected cohort [29] . Overall attrition of CD4 counts with time was not significantly different between the two groups. However, in patients with an initial CD4 count above 600 · 10 6 L )1 there was a significantly more rapid reduction with time in the coinfected patients.
In 2000 Greub et al. published the results of the Swiss HIV Cohort Study, a prospective study of over 3000 HIV-positive patients on HAART [30] . At a median follow-up of 28 months 6.6% of HIVmonoinfected patients progressed to AIDS compared with 9.7% and 15% of HCV-seropositive patients who were past or active intravenous drug users, respectively. The relative risk of developing an AIDSdefining illness or death in the coinfected group was 1.7 compared with HCV-seronegative patients. HCV infection was not associated with a reduction in the probability of HIV-infected patients achieving HIV suppression below 400 copies mL )1 . However, following initiation of HAART-coinfected patients had impaired CD4 count recovery compared with HIVmonoinfected individuals. In a study of a subset of patients the level of HCV viraemia was not found to be an influencing factor in CD4 cell count recovery. This observation has been confirmed in a similar study on a cohort of UK HIV-infected haemophilic patients commencing HAART [31] . In the Swiss Cohort Study HCV genotype 3 was associated with a more blunted CD4 count recovery. However, in a UK study, Sabin et al. reported that HIV-infected haemophilic patients coinfected with HCV genotype 1 had a worse prognosis compared with other genotypes [32] . Following Greub's publication a US study of almost 2000 HIV-infected patients with a similar median follow-up reported that HCV coinfection was not associated with an increased risk of progression to AIDS or death or impairment of the immunological response to HAART [33] .
The differences between the Swiss and US studies may be explained by variability in the patient groups [33] . In the Swiss study HCV-infected patients tended to be younger, white and female whereas in the US study patients were older and more likely to be African-American.
Whether HCV infection does worsen the outcome of HIV infection the mechanism has not been elucidated. Possible mechanisms that have been suggested include HCV-mediated direct impairment of CD4 cell production or sensitization of CD4 cells to apoptosis [34] .
In three recent studies, including one of haemophilic patients, the hepatitis G virus (HGV) has been reported to be associated with improved survival in HIV infection [35, 36] . It is therefore possible that if HCV does have an adverse effect on the course of HIV, the presence of persistent HGV infection may alleviate this effect to some degree. However, this remains to be proved.
Effect of HAART on HCV infection
Two European studies, one of a cohort of haemophilic patients, reported that the initial period of HAART was not associated with significant elevations in serum transaminase levels and HCV viraemia [37, 38] . However, other studies have reported contrary observations. In a study of 21 coinfected haemophilic patients Ragni and Bontempo observed an increase in HCV viraemia in 17 individuals during a 96-week period following commencement of HAART [39] . However, this was not associated with evidence of progression of HCV liver disease, although one patient did progress to liver failure during the first year of HAART. Other studies have observed rises in HCV viraemia and transaminases following commencement of HAART consistent with immune reconstitution-mediated reactivation of HCV liver disease [40] [41] [42] [43] . In the study of Vento et al., which included 51 coinfected patients followed up for a 9-month period, there were transient rises in HCV and transaminase levels following commencement of HAART peaking at 1 month. Thirty-one patients who underwent liver biopsy showed an increase in mean Knodell histological score from 8 before HAART to 13 on HAART. This was due to increased necroinflammatory activity consistent with reactivation of an immune-mediated attack on HCV as a consequence of HAARTinduced immune reconstitution. Seven of the patients in this study progressed to decompensated liver disease during the study period and had HAART discontinued [42] .
Effects of HIV drugs on the liver
If worsening of pre-existing transaminitis or new transaminitis occurs in coinfected patients commenced on HAART direct drug-related toxicity must be considered as a possible cause and not be assumed to be due to an immune reconstitutionmediated exacerbation of HCV infection. Pre-existing liver disease predisposes to HIV drug-induced liver toxicity [44, 45] . All the licensed nucleoside reverse transcriptase inhibitor drugs (NRTIs) can cause elevation of liver enzymes and have been associated with the development of hepatitic steatosis with hepatomegaly [46] . Stavudine and didanosine are the most likely of the NRTIs to be associated with hepatic steatosis and accompanying hyperlactataemia or occasionally potentially life-threatening lactic acidosis. Abacavir may be associated with the development of deranged liver function as part of a multi-organ hypersensitivity reaction which may develop within a few days or weeks of commencement. Liver function test abnormalities associated with the other drugs in this group result from direct drug toxicity. The mechanism of this effect is likely to be a consequence of hepatocellular mitochondrial toxicity.
The licensed non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz and nevirapine have also been associated with hepatic toxicity. Efavirenz can cause direct hepatocellular damage with elevation of liver enzymes, especially in patients with hepatitis B or C. Nevirapine can cause derangement of liver function with potentially life-threatening fulminant hepatitis as part of a generalized immunemediated hypersensitivity reaction which can occur within the first 2 months of treatment [47] . The risk of nevirapine-associated hypersensitivity is directly correlated with the CD4 count, reducing as immune function declines [48] . Nevirapine can also cause direct dose-dependent hepatotoxicity occurring after at least 4 months of therapy, especially in patients with hepatitis C coinfection [45] .
Although the earlier protease inhibitor drugs (PIs) indinavir, ritonavir and saquinavir were associated with liver toxicity [42, 49] this does not appear to be a problem with the newer agents amprenavir, nelfinavir and lopinavir/ritonavir combination.
All HIV medications should be used with caution in patients with HCV-associated hepatic impairment with regular monitoring of liver function. Patients on NRTIs or NNRTIs should be monitored closely for the possible development of hepatic steatosis, hyperlactataemia and lactic acidosis. Medications should be suspended or permanently discontinued if deterioration in liver function occurs.
Management of HCV in HIV infection
HIV-infected haemophilic patients are likely to have been previously screened for HCV infection using an HCV antibody test. Virtually all will have been found to have a positive test consistent with past exposure to HCV in factor concentrates. However, around 15% of individuals will naturally eradicate the virus and therefore it is important to determine whether HCV infection is still present by performing a polymerase chain reaction (PCR) test for HCV RNA. If the patient is HCV RNA positive, quantitation of the virus should be performed and the genotype determined. HIV-infected patients who are antibody negative should have an HCV RNA test performed as false negative antibody tests can occur as a consequence of immunosuppression [50] .
Coinfected patients with intermittent or persistent transaminitis should be considered for HCV eradication therapy. A liver biopsy is commonly performed in the assessment of HCV infection. There has been concern in the past over the safety of this procedure in haemophilic patients due to the potential for bleeding [51] . However, provided effective factor concentrate replacement protocols are followed the risk does not appear to exceed that of patients who do not have a bleeding disorder [52, 53] . Due to the potential for HCV infection to proceed to end-stage liver disease a good case can be made for initiating HCV treatment without information on liver histology. However, histological findings can be very useful in informing management decisions both for the clinician and the patient. Not uncommonly, minimal hepatitic changes may be present making it unlikely that HCV infection will progress at any time in the future to cirrhosis and liver failure. In this circumstance treatment could reasonably be withheld. Equally if advanced cirrhosis is present a decision may be taken not to proceed with treatment due to the reduced chances of HCV eradication.
In HCV RNA-positive patients with persistently normal hepatic transaminases a liver biopsy should be considered as progressive liver disease cannot be excluded. HCV therapy should only be offered if significant liver disease is present on histology [50] .
Treatment of HCV in HIV infection
HCV treatment strategy in HIV-infected patients is the same as in immunocompetent patients. Individuals with stable HIV infection and well preserved CD4 counts not on HAART should be strongly advised to consider HCV treatment. The HCVassociated hepatic necroinflammatory process is most active at this stage of HIV infection due to relatively preserved immune function and HCV eradication should be attempted at this stage before significant fibrosis develops. Furthermore, eradication of HCV at this stage will remove the adverse influence of HCV on the course of HIV infection and reduce the risk of HAART drug-induced hepatotoxicity if HIV therapy is required at any time in the future.
HIV-infected patients who are stable on HAART should be assessed on an individual basis. Treatment should be considered in stable patients with CD4 counts >200 · 10 6 L )1 . Coinfected individuals with progressive HIV disease and low CD4 counts should have HAART commenced as a priority. HCV treatment should be considered only when HIV infection is stabilized and CD4 counts improve. Patients with advanced HIV infection and hepatic decompensation should not be considered for HCV treatment.
The treatment of choice for HCV is combination therapy with pegylated interferon (Peg-IFN) and ribavirin. Peg-IFN is a formulation of alpha-interferon complexed with polyethylene glycol (Peg). It is administered subcutaneously and the formulation enables sustainment of therapeutic interferon levels which allows a once-weekly dosing schedule. At present there are two preparations: peg-alpha-2b interferon (Pegasys; Roche Products Ltd., Welwyn Garden City, UK) and peg-alpha-2a interferon (PegIntron; Schering-Plough Ltd., Welwyn Garden City, UK). Ribavirin, an analogue of the DNA base guanosine, is taken orally twice daily. To optimize therapy it is important that ribavirin is prescribed at the correct dose for body weight [54] . Patients commenced on combination therapy should be advised to abstain from alcohol.
In HIV-negative patients Peg-IFN/ribavirin combination therapy can achieve HCV eradication rates of just over 40% for HCV genotype 1 and up to 80% for genotypes 2 and 3 [55, 56] . Besides eradicating HCV, combination therapy reduces the degree of hepatic fibrosis [56, 57] . Even in non-responders a course of interferon therapy can slow fibrosis progression and reduce the risk of end-stage liver disease and the development of hepatocellular carcinoma [58] . In a review of seven studies of HIV/HCVcoinfected individuals with a combined total of 198 patients conventional interferon/ribavirin combination therapy resulted in an overall HCV RNA clearance rate of 25% (ranging from 17% to 40%) [54] . In three studies with a combined total of 63 patients who had failed to respond or had relapsed following a course of interferon monotherapy the overall response to conventional interferon/ribavirin therapy was slightly lower at 22% (ranging from 14% to 35%) [54] .
Factors predictive of a favourable response to combination therapy in coinfected patients include a CD4 cell count of >500 · 10 6 L )1 and plasma HIV RNA levels of <10 4 copies mL )1 [59, 60] . Poorer results in patients with lower CD4 counts may be due to the presence of more advanced fibrosis in this group, a known predictive factor of reduced response to IFN [61] . Other favourable predictive factors in common with HCV-monoinfected patients include non-genotype 1 HCV infection, low HCV load (<3.5 · 10 6 copies mL
), age <40 and abstinence from alcohol [54, 62] .
The initial study looking at the efficacy of peg-IFN/ ribavirin in coinfected patients reported an endof-treatment response of 65% [54] . Data on the sustained response rate is awaited. Interim analysis of a similar trial reported a 44% response rate to peg-IFN/ribavirin at 24 weeks [63] . A number of larger studies of peg-IFN/ribavirin in coinfected patients are ongoing.
Patients commenced on peg-IFN/ribavirin should have an HCV RNA test performed at 3 and 6 months. Although the majority of responders become HCV RNA negative by 3 months, treatment should be continued in those who remain RNA positive as later responses have been reported [64] . If the 6-month RNA test is positive therapy should be discontinued as a response beyond this time is very unlikely. A recent trial has suggested that persistence of detectable HCV RNA at 3 months is a strong predictor of response failure in coinfected patients [55] . Therefore, a case could be made for discontinuing therapy at this early stage in non-responders, so avoiding unnecessary drug treatment and possible toxicity. Patients with genotype 1 infection who have cleared HCV RNA by 6 months should have treatment continued for a full 12 months to consolidate the response. Responders with non-genotype 1 virus can have treatment discontinued at 6 months [50] . Following cessation of therapy responders should have regular HCV RNA monitoring and if relapse occurs further combination therapy should be considered.
Side-effects of interferon and ribavirin and interactions with HAART drugs
The main side-effects of peg-IFN are similar to conventional preparations and include flu-like symptoms, lethargy, depression and cytopenias. IFN can induce a reduction in CD4 lymphocyte counts in some individuals. This is likely to be a consequence of pooling of the lymphocytes within lymphoid tissue and is usually transient. Occasionally the fall in CD4 count can be severe enough to necessitate cessation of IFN and may be irreversible [65] . Ribavirin is associated with the development of a dose-dependent haemolytic anaemia. Haemoglobin levels can fall below 11 g dL )1 in up to 35% of patients [66] . Anaemia is not usually clinically significant but may be severe enough to cause symptoms. This effect of ribavirin may compound zidovudine-induced anaemia in patients on this drug. Symptomatic patients can be effectively treated with recombinant human erythropoietin, which is preferable to reducing the ribavirin dose with the potential reduction in its anti-HCV effect [67] .
With regard to interactions with HIV drugs ribavirin is known to inhibit the intracellular phosphorylation of zidovudine, stavudine and zalcitabine in vitro. This has the potential to reduce the efficacy of these drugs in vivo but there is no evidence that this interaction is clinically significant [68] [69] [70] . Ribavirin enhances the phosphorylation of didanosine [54] . Although this may enhance the anti-HIV effect of didanosine there have been reports of an increased incidence of mitochondrial toxicity in patients on both drugs manifesting clinically as weight loss, pancreatitis, hyperlactataemia or at its most extreme lactic acidosis [71, 72] . Stavudine and to a lesser extent the other NRTIs appear to have similar interactions with ribavirin [73] . Therefore, patients receiving HCV combination therapy and HAART regimens containing NRTIs should be monitored very closely, and for those on didanosine consideration given to changing to an alternative drug.
Liver transplantation for HCV liver disease in coinfected patients
Patients who develop HCV related liver failure or localised hepatocellular carcinoma who have stable HIV infection on or off HAART should be considered for liver transplantation. Prior to HAART the prognosis in this group of patients was very poor [74] . In the series reported by Gordon et al the one year and three year survival in the six HIV positive haemophilic patients was 67% and 23% respectively which was significantly worse than that of the 19 HIV negative patients (90% and 83% respectively) [75] . However with the marked improvement in the management of HIV infection graft survival rates at one year post liver transplantation in this patient group is now around 80%, similar to that of HIV negative patients [76}. At the time of writing an HIV positive haemophilic patient transplanted in Birmingham UK remains alive and well four years post transplant [77] . A second patient transplanted in early 2003 also remains well. HIV infection should therefore not be considered a contraindication to liver transplantation.
Conclusions
• It is well established that HIV infection worsens the prognosis of HCV liver disease.
• There is also evidence that HCV has a detrimental effect on the course of HIV infection.
• HCV infection should therefore be actively managed in coinfected patients.
• Patients who are considered to require treatment who have stable HIV infection either on or off HAART with CD4 counts >200x106/l should be treated with Peg-IFN / ribavirin combination therapy.
• Close clinical and laboratory monitoring is recommended to screen for possible drug side effects and interactions.
• As in immunocompetent individuals responders with genotype 1 virus should continue treatment for 12 months and those with non-genotype 1 virus for six months.
• Individuals with end stage liver disease with stable HIV infection should be considered for liver transplantation.
